GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Staidson (Beijing) Biopharmaceuticals Co Ltd (SZSE:300204) » Definitions » Intrinsic Value: Projected FCF

Staidson (Beijing) Biopharmaceuticals Co (SZSE:300204) Intrinsic Value: Projected FCF : ¥-1.57 (As of Jun. 05, 2025)


View and export this data going back to 2011. Start your Free Trial

What is Staidson (Beijing) Biopharmaceuticals Co Intrinsic Value: Projected FCF?

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company. The details of how we calculate the intrinsic value of stocks are described in detail here.

As of today (2025-06-05), Staidson (Beijing) Biopharmaceuticals Co's Intrinsic Value: Projected FCF is ¥-1.57. The stock price of Staidson (Beijing) Biopharmaceuticals Co is ¥30.42. Therefore, Staidson (Beijing) Biopharmaceuticals Co's Price-to-Intrinsic-Value-Projected-FCF of today is 0.0.

The historical rank and industry rank for Staidson (Beijing) Biopharmaceuticals Co's Intrinsic Value: Projected FCF or its related term are showing as below:

During the past 13 years, the highest Price-to-Intrinsic-Value-Projected-FCF of Staidson (Beijing) Biopharmaceuticals Co was 202.00. The lowest was 1.40. And the median was 2.53.

SZSE:300204's Price-to-Projected-FCF is not ranked *
in the Biotechnology industry.
Industry Median: 2.16
* Ranked among companies with meaningful Price-to-Projected-FCF only.

Staidson (Beijing) Biopharmaceuticals Co Intrinsic Value: Projected FCF Historical Data

The historical data trend for Staidson (Beijing) Biopharmaceuticals Co's Intrinsic Value: Projected FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Staidson (Beijing) Biopharmaceuticals Co Intrinsic Value: Projected FCF Chart

Staidson (Beijing) Biopharmaceuticals Co Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Intrinsic Value: Projected FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 4.35 2.90 1.21 -0.79 -1.52

Staidson (Beijing) Biopharmaceuticals Co Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Intrinsic Value: Projected FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -1.22 -2.19 -1.48 -1.52 -1.57

Competitive Comparison of Staidson (Beijing) Biopharmaceuticals Co's Intrinsic Value: Projected FCF

For the Biotechnology subindustry, Staidson (Beijing) Biopharmaceuticals Co's Price-to-Projected-FCF, along with its competitors' market caps and Price-to-Projected-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Staidson (Beijing) Biopharmaceuticals Co's Price-to-Projected-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Staidson (Beijing) Biopharmaceuticals Co's Price-to-Projected-FCF distribution charts can be found below:

* The bar in red indicates where Staidson (Beijing) Biopharmaceuticals Co's Price-to-Projected-FCF falls into.


;
;

Staidson (Beijing) Biopharmaceuticals Co Intrinsic Value: Projected FCF Calculation

Since the intrinsic value calculations based on Discounted Cash Flow Intrinsic Value: DCF (FCF Based), or Discounted Earnings Intrinsic Value: DCF (Earnings Based) cannot be applied to companies without consistent revenue and earnings, GuruFocus developed a valuation model based on normalized Free Cash Flow and Book Value of the company.

The details of how we calculate the intrinsic value of stocks are described in detail here.

This method smooths out the free cash flow over the past 6-7 years, multiplies the results by a growth multiple, and adds a portion of Total Stockholders Equity.

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + 0.8 * Total Stockholders Equity (most recent) ) / Shares Outstanding (Diluted Average)

In the case of negative Total Stockholders Equity, the following formula is used (see Explanation section below for the reason):

Intrinsic Value: Projected FCF = ( Growth Multiple * Free Cash Flow (6 year avg) + Total Stockholders Equity (most recent) / 0.8 ) / Shares Outstanding (Diluted Average)


Add all the Free Cash Flow together and divide 6 will get Staidson (Beijing) Biopharmaceuticals Co's Free Cash Flow(6 year avg) = ¥-159.15.

Staidson (Beijing) Biopharmaceuticals Co's Intrinsic Value: Projected FCF for today is calculated as

Intrinsic Value: Projected FCF=(Growth Multiple*Free Cash Flow (6 year avg)+Total Stockholders Equity (Mar25)*0.8)/Shares Outstanding (Diluted Average)
=(9.5203515959648*-159.14928+953.43*0.8)/477.773
=-1.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Staidson (Beijing) Biopharmaceuticals Co  (SZSE:300204) Intrinsic Value: Projected FCF Explanation

The growth multiple is capped between 8.35 and 17.74.

Total Stockholders Equity weighting is more art than science and it should always be revisited in more detail when researching a company. Weightings from 0% to 100% to more than 100% are possible. 80% was chosen as a happy median after taking the above ideas into consideration.

Staidson (Beijing) Biopharmaceuticals Co's Price-to-Intrinsic-Value-Projected-FCF for today is calculated as

Price-to-Intrinsic-Value-Projected-FCF=Share Price/Intrinsic Value: Projected FCF
=30.42/-1.5748338684787
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Staidson (Beijing) Biopharmaceuticals Co Intrinsic Value: Projected FCF Related Terms

Thank you for viewing the detailed overview of Staidson (Beijing) Biopharmaceuticals Co's Intrinsic Value: Projected FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Staidson (Beijing) Biopharmaceuticals Co Business Description

Traded in Other Exchanges
N/A
Address
Rongjing Dong Street, No 5 Beijing Economic and Technological Development Zone, Beijing, CHN, 100176
Staidson (Beijing) Biopharmaceuticals Co Ltd is a pharmaceutical company mainly engaged in the research, development, production, and sale of biological products in China. Its products include mouse nerve growth factor injection, intravenous compound polyethylene glycol electrolyte powder solution, gliclazide, nabumetone, and aspirin.
Executives
Zhang Hong Shan Supervisors
Zheng Hong Supervisors
Cheng Jiang Hong Executives
Feng Yu Jing Executives
Ma Li Na Secretary, Director
Zhou Zhi Wen Director
Wang Huan Securities Affairs Representative
Zhang Rong Qin Executives
Xu Jiang Ping Executives
Cao Hai Yan Supervisors
Sun Yan Fang Executives
Jiang Li Xin Director
Gu Jian Ping Director
Xu Xiang Qing Supervisors
Gu Zhen Qi Director

Staidson (Beijing) Biopharmaceuticals Co Headlines

No Headlines